Home  »  Markets   »  Fate Therapeutics Inc. (FATE) Analysis & Fore...

Fate Therapeutics Inc. (FATE) Analysis & Forecast for 2023

Fate Therapeutics Inc. (NASDAQ: FATE) is -46.18% lower on its value in year-to-date trading and has touched a low of $4.02 and a high of $43.14 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The FATE stock was last observed hovering at around $5.55 in the last trading session, with the day’s loss setting it -0.12%.

Currently trading at $5.43, the stock is -30.07% and -61.89% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.64 million and changing -2.16% at the moment leaves the stock -76.95% off its SMA200. FATE registered -85.38% loss for a year compared to 6-month loss of -82.34%.

5 Undervalued Stocks For 2023

Approximately 544 miles north of Las Vegas lies what's been dubbed "the biggest lithium deposit in the US." One tiny company stands to be the biggest beneficiary because lithium "faces a long-term supply shortage," according to Barron's. This company, however, is sitting on a goldmine opportunity as it plans to produce 30,000 tonnes per annum over the next 3.5 years from this single deposit. Supplying the electric vehicle boom and potentially driving its stock price off the charts. But this is just one of the opportunities we have researched in our free report. The other four companies have just as much potential.

Click here to download your Free Copy…

Sponsored

The stock witnessed a -55.67% gain in the last 1 month and extending the period to 3 months gives it a -71.85%, and is -5.07% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 5.66% over the week and 8.71% over the month.

Fate Therapeutics Inc. (FATE) has around 449 employees, a market worth around $545.01M and $69.00M in sales. Distance from 52-week low is 35.07% and -87.41% from its 52-week high. The company has generated returns on investments over the last 12 months (-32.00%).

Fate Therapeutics Inc. (FATE) Analyst Forecasts

Analyst recommendations provided by FactSet shows that the consensus forecast for Fate Therapeutics Inc. (FATE) is a “Hold”. 24 analysts offering their recommendations for the stock have an average rating of 2.60, where 15 rate it as a Hold and 1 think it is a “Overweight”. 6 of the analysts rate the stock as a “Buy”. 1 analysts have rated the stock as a Sell or Underperform.

Fate Therapeutics Inc. is expected to release its quarterly report on 05/03/2023.The EPS is expected to shrink by -6.40% this year.

Fate Therapeutics Inc. (FATE) Top Institutional Holders

The shares outstanding are 97.02M, and float is at 95.67M with Short Float at 23.34%.

Fate Therapeutics Inc. (FATE) Insider Activity

A total of 8 insider transactions have happened at Fate Therapeutics Inc. (FATE) in the last six months, with sales accounting for 8 and purchases happening 0 times. The most recent transaction is an insider purchase by MENDLEIN JOHN,the company’sDirector. SEC filings show that MENDLEIN JOHN bought 36,631 shares of the company’s common stock on Jan 13 at a price of $5.43 per share for a total of $0.2 million. Following the purchase, the insider now owns 0.28 million shares.

Fate Therapeutics Inc. disclosed in a document filed with the SEC on Jan 11 that MENDLEIN JOHN (Director) bought a total of 88,048 shares of the company’s common stock. The trade occurred on Jan 11 and was made at $5.67 per share for $0.5 million. Following the transaction, the insider now directly holds 0.25 million shares of the FATE stock.

Still, SEC filings show that on Jan 10, Valamehr Bahram (Chief R&D Officer) disposed off 10,917 shares at an average price of $5.24 for $57205.0. The insider now directly holds 168,917 shares of Fate Therapeutics Inc. (FATE).

Fate Therapeutics Inc. (FATE): Who are the competitors?

The company’s main competitors (and peers) include Ionis Pharmaceuticals Inc. (IONS) that is trading 34.10% up over the past 12 months and Neurocrine Biosciences Inc. (NBIX) that is 44.69% higher over the same period. Becton Dickinson and Company (BDX) is -4.75% down on the 1-year trading charts.

Most Popular

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Related Posts